We previously found that a reduction in brain CS by injection of anti-ouabain antibodies significantly inhibited AMPH-induced hyperactivity (Hodes, Rosen et al. 2016). As behavioral tests are extremely sensitive to environmental and experimental conditions, we considered it important to validate our previous findings in the animals that were used in the subsequent biochemical assays. In agreement with the published findings mentioned above, we observed significant effects on three parameters of mobility that were tested in the open field test: total distance moved (One-way ANOVA: F3,20 = 7.24; p = 0.002), duration of mobility (F3,20 = 7.02; p = 0.002) and mean velocity (F3,20 = 7.16; p = 0.002). As shown in Fig. 1, administration of AMPH caused a significant increase in mobility compared with that of the control group Posthoc Holm-Sidak test for distance moved, duration of mobility and mean velocity; p < 0.005). Administration of anti-ouabain antibodies markedly reduced the AMPH-induced hyperactivity (p< 0.01). No difference was found between the control group and the anti-ouabain antibodies group.